TTD: Valuation nearly full at VND 107,466; execution and liquidity risks keep premium limited
Intrinsic value VND 107,466 vs market price VND 106,000 => implied upside 1.4% (confidence: very_low).
Business Overview
Công ty Cổ phần Bệnh viện Tim Tâm Đức (TTD) operates in private healthcare under ICB 3 "Thiết bị và Dịch vụ Y tế" and is listed on UPCOM. The group provides cardiovascular hospital services and related medical procedures; revenue increased from VND 741.2 bn in 2023 to VND 835.8 bn in 2025. The company is a small-cap with 31,104,000 shares outstanding and modest trading liquidity (avg volume 2w = 502 shares).
Investment Thesis
TTD presents a mature, profitable hospital franchise: ROE is 28.0% and ROA 22.9% with Net Profit Margin 11.5% and EPS of VND 6,156, supporting a trailing P/E ~16.2x. Revenue grew 7.4% YoY into 2025 and net profit rose to VND 95.7 bn in 2025, indicating continued demand for cardiovascular services. The valuation model blends a DCF (70%) and a P/E approach (30%) to produce an intrinsic of VND 107,466 per share, roughly in line with the market price (implied upside 1.4%).
However, our confidence in the intrinsic estimate is very_low. The model's raw DCF and P/E legs diverge materially (DCF intrinsic VND 31,515; P/E intrinsic VND 99,600) and the calibrated raw intrinsic before isotonic adjustment was VND 51,940, indicating sensitivity to methodology and inputs. Trading is thin (avg volume 502) and UPCOM listing plus zero foreign room limit institutional demand. Given the narrow implied upside (1.4%) and significant model uncertainty, the expected return does not compensate sufficiently for execution, liquidity and re-rating risk.
Valuation Commentary
Blend of a 10-year FCF DCF (70%) and a P/E multiple approach (30%), calibrated via isotonic mapping to produce the final intrinsic value.
- WACC 10.09% and terminal growth 4.0% underpin the DCF; TV accounts for 56.6% of total value in the model.
- DCF leg produces VND 31,515 per share; P/E leg (fair P/E 16.18x, cap 25x) produces VND 99,600 per share; blend weights are 70%/30%.
- Model raw intrinsic prior to calibration was VND 51,940; calibrated intrinsic is VND 107,466, reflecting strong isotonic adjustment and model instability.
- Net balance-sheet position is reported as net cash (net_debt negative), supporting equity value and lowering leverage (Debt/Equity 0.231).
The blended intrinsic value is effectively in-line with the current market price, leaving only 1.4% upside. Confidence is very_low because the DCF and P/E legs diverge sharply and the model required heavy calibration (raw intrinsic VND 51,940 -> calibrated VND 107,466). We view the estimate as fragile to changes in WACC, terminal growth and the P/E cap.
Bull vs Bear
- High capital efficiency: ROE 28.0% and ROA 22.9% indicate strong returns on invested capital.
- Profitability and margin stability: Net Profit Margin 11.5% and EBIT Margin 11.9% with 2025 net profit of VND 95.7 bn.
- Net cash position and low leverage (Debt/Equity 0.231) reduce balance-sheet risk and support reinvestment or dividends (dividend yield 3.3%).
- Valuation fragile: DCF and P/E intrinsic legs diverge (VND 31,515 vs VND 99,600) and raw model intrinsic (VND 51,940) required isotonic calibration to reach VND 107,466.
- Liquidity & market access constraints: avg volume 2w = 502 shares, listed on UPCOM with foreign_room 0.0 limiting demand from institutional and foreign investors.
- Model confidence very_low and san ity flag 'illiquid' suggest higher execution risk; narrow implied upside 1.4% offers little cushion against adverse outcomes.
Sector Context
Vietnam private healthcare sits amid growing demand for specialized services but faces regulatory and operating nuances: VAS accounting can differ from IFRS/IFRS for recognition of some hospital receivables; public hospitals and insurance reimbursements influence pricing and patient flows. Peers in the medical services cohort show median implied upside ~12.1%, while top peers in the dataset show much larger upside — contrast that TTD's 1.4% implied upside is at the low end. UPCOM listing and zero foreign room are common constraints for mid/small-cap health names and limit re-rating potential versus HOSE/HNX-listed peers. SBV credit quotas and state-related payment practices can indirectly affect elective procedure demand and hospital working capital cycles. For healthcare, land use rights and facility expansion approvals are key for growth; hospital capex and licensing can materially change future revenue paths.
Risk Factors
- Very low model confidence: valuation labelled 'very_low' and model required isotonic recalibration from raw intrinsic VND 51,940 to calibrated VND 107,466.
- Liquidity risk: avg volume 2w = 502 shares and UPCOM listing; limited tradability increases execution cost for larger flows.
- Concentration of ownership: top five shareholders collectively hold ~35.1% (largest holder 10.71%), which can limit free float and corporate governance dynamics.
- Revenue sensitivity to elective procedure demand and insurance reimbursements; a slowdown could compress margins (current Net Profit Margin 11.5%).
- Regulatory and licensing risk for hospital expansions and medical practice permits; increases in compliance costs could reduce ROIC, currently implied at 27.6% in the model inputs.
- Model sensitivity to macro inputs: WACC 10.09% and terminal growth 4.0% — adverse moves would materially reduce DCF value, and TV accounts for 56.6% of value.
Catalysts
- Improved liquidity or move to HOSE/HNX (if pursued) could unlock re-rating by expanding investor base.
- Better-than-expected margin expansion or revenue growth (2025 revenue VND 835.8 bn, net profit VND 95.7 bn) would increase visible upside versus current price.
- Clarity or reduction in ownership concentration (greater free float) may attract institutional interest.
- Positive regulatory developments around insurance reimbursements or approval of additional specialist services/wards.
Forensic Assessment
No M-Score is available and there are no forensic red flags recorded; earnings quality is high at 93.4/100. Given the absence of M-Score flags and the strong earnings-quality metric, there are no immediate forensic concerns. The main caveat is the model's calibration adjustments and the UPCOM listing/illiquidity rather than accounting manipulation.
Track Record
Model track record spans 10 years (2017–2026) with a hit rate of 55.6% and average realized upside when correct of 19.4%. The historical hit rate is modestly above coin-flip, supporting some use of the methodology, but the very_low confidence for this specific valuation and the need for isotonic recalibration warrant caution when relying on the point estimate.
Written by a language model on 2026-08-10 from this page’s own model outputs and financial statements, and may quote figures from that date. Descriptive analysis, not investment advice — no buy, sell or hold recommendation is given or implied.